The company recently guided for FY24 revenue of $428M-$432M, consensus $430.97M. Analysts expect the company to report FY25 revenue of $543.99. Guidance taken from Investor Day. Shares of TransMedics (TMDX) are down 3.4% in afternoon trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX: